FDA Halts Allogene CAR-T Cell Therapy Trial
A patient dosed with Allogene’s off the shelf CAR-T therapy for cancer developed “chromosomal abnormalities” prompting the FDA to suspend the clinical trial while it investigates the event. The therapy, ALLO-501A was applied to a patient with B-cell follicular lymphoma. The patient subsequently lost the ability to produce sufficient blood cells. Read more here: https://www.statnews.com/2021/10/07/fda-halts-allogene-blood-cancer-trials-after-patient-found-to-have-chromosomal-abnormality/?utm_source=STAT+Newsletters&utm_campaign=593893c461-RO_COPY_04&utm_medium=email&utm_term=0_8cab1d7961-593893c461-151602985